Healthcare Industry News: OraSure Technologies
News Release - July 29, 2009
Diagnostic Executive Joins Metabolon
Senior Vice President to Lead the Company’s Diagnostic ProgramsRESEARCH TRIANGLE PARK, N.C.--(HSMN NewsFeed)--Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced that Joseph E. Zack has joined the company as senior vice president of diagnostics. Mr. Zack will provide strategic direction and commercial leadership in bringing Metabolon’s diagnostic products to market.
Metabolon’s pioneering metabolomics technology enables the global analysis of complex biological samples and the rapid identification of a wide range of biochemical markers and pathways in virtually any disease or disease state. The company is developing a series of high-value diagnostic tests using this non-targeted approach, with key programs in prostate cancer* and diabetes.
“The wide-spread growth of the molecular diagnostics market and our unique and patented ability to apply metabolomics for disease biomarker discovery presents an exciting opportunity for Metabolon,” commented John Ryals, Metabolon’s CEO. “Joe’s extensive expertise in launching new and innovative diagnostic products will be a valuable asset as we continue to build the infrastructure to support our diagnostic business.”
Mr. Zack has over 30 years of broad business experience in the biopharmaceutical and diagnostic industry, building organizations and launching new products. Prior to Metabolon, he was executive vice president, marketing and sales for OraSure Technologies, where he grew and expanded the company’s diagnostic and device business. Mr. Zack also served as vice president, sales and marketing for OraPharma, where he built and led all commercial operations from start-up through IPO. He has also worked with companies including Advanced Tissue Sciences and Ciba-Geigy Pharmaceuticals (now Novartis). Mr. Zack has a B.A. from Colgate University and an MBA from St. John’s University.
About Metabolon
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.
*Editor’s Note: See the February 11, 2009 press release announcing the discovery of biomarkers of prostate cancer progression published in Nature. (Sreekumar, A, et al. Metabolomic Profiles Delineate Potential Role for Sarcosine in Prostate Cancer Progression. Nature 457:910-914 (2009))
Source: Metabolon
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
